KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Common Equity: 2009-2024

Historic Common Equity for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$623.8 million.

  • Novavax's Common Equity rose 70.24% to -$156.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.7 million, marking a year-over-year increase of 70.24%. This contributed to the annual value of -$623.8 million for FY2024, which is 12.98% up from last year.
  • Per Novavax's latest filing, its Common Equity stood at -$623.8 million for FY2024, which was up 12.98% from -$716.9 million recorded in FY2023.
  • In the past 5 years, Novavax's Common Equity ranged from a high of $627.2 million in FY2020 and a low of -$716.9 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was -$634.1 million (2022), whereas its average is -$658.3 million.
  • In the last 5 years, Novavax's Common Equity soared by 437.18% in 2020 and then plummeted by 156.07% in 2021.
  • Yearly analysis of 5 years shows Novavax's Common Equity stood at $627.2 million in 2020, then crashed by 156.07% to -$351.7 million in 2021, then tumbled by 80.30% to -$634.1 million in 2022, then decreased by 13.07% to -$716.9 million in 2023, then increased by 12.98% to -$623.8 million in 2024.